- Acquired by Artivion, May 2026
- Raised $25M funding round led by Artivion, Jul 2024
- Raised $15M funding round led by CryoLife, Sep 2019
About
Endospan develops low-profile stent graft systems for treating aneurysms and dissections throughout the aorta, including infrarenal, visceral, and thoracic. Endospan helps make the treatment of aneurysms, dissections, and aortic lesions simpler and less invasive, making it a suitable choice for patients with limited treatment options. Endospan's HORIZON system can be used in a single-sided approach, generally shortening and simplifying EVAR procedures. It is especially useful for patients for whom a two-sided approach is physically impossible because of occlusions, natural anatomical contraindications, or other pathologies arising from prior surgical intervention. The company's NEXUS is an aortic stent graft system whose modular approach offers a minimally invasive endovascular solution for patients diagnosed with an aneurysm in the ascending aorta or the aortic arch. In March 2019, Endospan announced that it received the CE Mark for its Nexus stent graft system to be used for branched endovascular repair in the aortic arch. In April 2020, the Nexus aortic arch stent graft system received FDA breakthrough device designation.
Funding history · 5 rounds · $20.0M total
Q&A
- What is the primary focus of EndoSpan?
- EndoSpan develops low-profile stent graft systems for treating aneurysms and dissections throughout the aorta, including infrarenal, visceral, and thoracic.
- When was EndoSpan acquired and by whom?
- EndoSpan was acquired by Artivion in May 2026.
- What is the status of EndoSpan's Nexus stent graft system?
- In March 2019, EndoSpan received the CE Mark for its Nexus stent graft system for branched endovascular repair in the aortic arch. In April 2020, the Nexus aortic arch stent graft system received FDA breakthrough device designation.
- How many employees does EndoSpan have?
- EndoSpan has 51-200 employees.
- What was EndoSpan's most recent funding round?
- In July 2024, EndoSpan raised $25,000,000 from Artivion.
- What is the total amount of funding EndoSpan has raised to date?
- EndoSpan has raised a total of $20,000,000 USD.
- Which investors participated in EndoSpan's October 2015 funding round?
- In October 2015, EndoSpan received funding from Xizang Haisco Pharmaceutical Group and Accelmed.
- When was EndoSpan founded?
- EndoSpan was founded in August 2008.
Team · 2
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | endospan.com |
|---|---|
| linkedin.com/company/17988904 | |
| facebook.com/EndospanLtd/timeline | |
| YouTube | youtube.com/channel/UCTUkswGXbpkg0Sskz_GcgMw |
Identifiers & details
| Founded | 2008-8 |
|---|---|
| Employees (exact) | 59 |
| Status reason | Acquired by Artivion on May 2026 |
Acquisitions & public offerings
Acquired by Artivion 2026-05
Radar intelligence
Patents
| EPO | 36 |
|---|
Publications (Crossref)
| Works | 2 |
|---|
Web history (Wayback)
| Domain | endospan.com |
|---|
Certificate / subdomain footprint
| Subdomains | 7 |
|---|